|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
1999-12-2
|
|
pubmed:abstractText |
Thymic irradiation (TI) or repeated administration of T cell-depleting monoclonal antibodies (TCD mAbs) is required in a previously described non-myeloablative regimen allowing allogeneic marrow engraftment with stable mixed chimerism and tolerance. As both treatments might be associated with toxicity in the clinical setting, we evaluated whether T-cell costimulatory blockade could be used to replace them.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Differentiation,
http://linkedlifedata.com/resource/pubmed/chemical/CD40 Ligand,
http://linkedlifedata.com/resource/pubmed/chemical/CTLA-4 Antigen,
http://linkedlifedata.com/resource/pubmed/chemical/Ctla4 protein, mouse,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoconjugates,
http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Membrane Glycoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/abatacept
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0041-1337
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
68
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1348-55
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:10573075-Animals,
pubmed-meshheading:10573075-Antibodies, Monoclonal,
pubmed-meshheading:10573075-Antigens, CD,
pubmed-meshheading:10573075-Antigens, Differentiation,
pubmed-meshheading:10573075-CD40 Ligand,
pubmed-meshheading:10573075-CTLA-4 Antigen,
pubmed-meshheading:10573075-Chimera,
pubmed-meshheading:10573075-Female,
pubmed-meshheading:10573075-Graft Survival,
pubmed-meshheading:10573075-Hematopoiesis,
pubmed-meshheading:10573075-Immune Tolerance,
pubmed-meshheading:10573075-Immunoconjugates,
pubmed-meshheading:10573075-Immunosuppressive Agents,
pubmed-meshheading:10573075-Lymphocyte Culture Test, Mixed,
pubmed-meshheading:10573075-Membrane Glycoproteins,
pubmed-meshheading:10573075-Mice,
pubmed-meshheading:10573075-Mice, Inbred C57BL,
pubmed-meshheading:10573075-Skin Transplantation,
pubmed-meshheading:10573075-Thymus Gland,
pubmed-meshheading:10573075-Transplantation Conditioning
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Anti-CD154 or CTLA4Ig obviates the need for thymic irradiation in a non-myeloablative conditioning regimen for the induction of mixed hematopoietic chimerism and tolerance.
|
|
pubmed:affiliation |
Transplantation Biology Research Center, Massachusetts General Hospital/Harvard Medical School, Boston 02129, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
